CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CTI BioPharma Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CTI BioPharma Corp
3101 Western Avenue, Suite 800
Phone: (206) 282-7100p:206 282-7100 SEATTLE, WA  98121  United States Fax: (206) 284-6206f:206 284-6206
This company was Merged or Acquired on 6/26/2023.
This company ceased filing statements with the SEC on 7/6/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
CTI BioPharma Corp. is a commercial biopharmaceutical company. It is focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers. Its commercially approved product, VONJO (pacritinib), is an oral kinase inhibitor with specificity for JAK2, mutant JAK2 form, IRAK1, ACVR1 (ALK2) and FLT3 for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. It is conducting the Phase III PACIFICA study of pacritinib in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, graft versus host disease (GvHD) and chronic lymphocytic leukemia (CLL) due to its inhibition of JAK2, IRAK1, FLT3, ACVR1 and CSF1R.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 Morningstar DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202312/31/2022YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board LaurentFischer 59 9/26/2017 7/21/2017
President, Chief Executive Officer, Interim Chief Medical Officer, Director Adam R.Craig 57 3/20/2017 3/20/2017
Chief Financial Officer, Executive Vice President, Secretary David H.Kirske 68 9/1/2017 9/1/2017
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Aequus Biopharma, Inc.
CEPS
Novuspharma SpA

General Information
Number of Employees: 128 (As of 12/31/2022)
Outstanding Shares: 131,880,176 (As of 5/4/2023)
Shareholders: 106
Stock Exchange: NASD
Federal Tax Id: 911533912
Fax Number: (206) 284-6206
Email Address: invest@ctiseattle.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, October 27, 2024